Canoga Perkins Announces Breakthrough Private 5G Transport Solution Enabling Time Sensitive Networking (TSN)
19.2.2025 07:00:00 CET | Business Wire | Press release
SyncMetra® 100 is a software-defined, IT-operated 5G network transport solution that guarantees ultra-low latency, deterministic wireless communications for industrial automation, enterprise AI, and AR/VR applications.
Network connectivity solutions provider, Canoga Perkins today announced that it has begun shipping evaluation units for its SyncMetra 100 transport solution, purpose-built to simplify the deployment, configuration, management, and expansion of low latency private 5G networks for industrial automation including TSN, enterprise AI, and AR/VR applications.
In addition, the company announced its upcoming presence at Mobile World Congress in Barcelona, March 3-6 (Hall 7 Stand 7C3Ex) and at Hannover Messe, March 31-April 4 where it will be demonstrating the SyncMetra solution.
"As advancements in AI, automation and IoT accelerate the proliferation of use cases, the market has been constrained to deploy deterministic wireless networks,” said Malik Arshad, President of Canoga Perkins. “We anticipated this gap and purpose-built SyncMetra to simplify the deployment, configuration, management, and expansion of private 5G networks to open new revenue streams for network owners and their system integrators, VARs and mobile network specialists.”
According to the company, with SyncMetra, IT teams can deploy private 5G networks as easily as Wi-Fi without over-reliance on telco expertise or cost-prohibitive infrastructure unlocking some of the market’s most powerful and promising emerging technologies including AI/ML, IoT, robotics, cloud computing, and edge data inference.
Key Features
The SyncMetrasuite of products introduces new capabilities enabling a programmable, expandable and more affordable alternative to current wireless technologies:
- Deterministic networking supporting real-time communication guaranteed Quality of Service (QoS)
- Ultra-reliable low-latency communications (URLLC), and precise packet delivery
- Software-defined and cloud-managed with centralized orchestration via SyncMetra ManagerTM (SMM)
- Seamless integration with existing IT infrastructure, reducing deployment complexity
- Mission-critical security with complete visibility and programmability
- Expandable architecture that allows businesses to scale as needed
Inquiries related to demonstrations and evaluation units are to be directed to www.canogaperkins.net/contact-2.
About Canoga Perkins
Founded in 1963, privately held Canoga Perkins has a long history of providing mission-critical, secure communications to service providers, the military, government agencies, and utilities. With more than 150,000 active network elements operating in Tier 1 service provider networks, Canoga Perkins is differentiated by the telco reliability of its products and its ability to anticipate and nimbly act on emerging IT trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218480924/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom